Pediatric Neuroblastoma Treatment Market by Treatment Type (Immunotherapy, Chemotherapy, and Radiation Therapy), Risk Group (Low Risk, Intermediate Risk and High Risk), End User (Hospitals and Cancer Specialty Centers) - Analysis & Forecast 2019-2030.
Report ID : 225 | Published Date : Feb 2020 | Pages : 175 | Region : Global | Report Code : PH-15
Pediatric Neuroblastoma Treatment Market Overview and Introduction
Neuroblastoma is the most common type of cancer found in infants & young children and accounts for up to 10% of the total pediatric cancer. It is caused due to embryonal malignancy of the sympathetic nervous system which arises from the neuroblasts. Neuroblastoma is most often found in the nerve tissues of adrenal glands. It may also develop in the abdominal part of the body including chest, neck or near spinal cord. Neuroblastoma rarely occurs after the age of around 10 years.
The global pediatric neuroblastoma treatment market is mainly driven by increasing prevalence of neuroblastoma in children, rising awareness about available treatments and improvements in the healthcare infrastructure. Moreover, rising R&D activities also play a pivotal role in contributing to market growth globally. However, high cost of this therapy associated with the treatment is likely to restrain market growth to a certain extent.
The global pediatric neuroblastoma treatment market can be segmented into treatment type, risk group, end users, and regions.
Pediatric Neuroblastoma Treatment Market By Treatment Type
Based on treatment type, the market is segmented into immunotherapy, chemotherapy, radiation therapy and others. The chemotherapy segment is expected to dominate the pediatric neuroblastoma treatment market during the forecast period. Chemotherapy is the treatment of choice owing to its effectiveness in slowing down the growth or spread of the disease. Furthermore, use of chemotherapy along with other treatments such as radiation therapy or surgery may give the optimum results. These overall factors are expected to boost the growth of this segment.
Pediatric Neuroblastoma Treatment Market by Risk Group
Based on risk group, the market can be segmented into low risk, intermediate risk and high risk. The high risk segment is expected to dominate the pediatric neuroblastoma treatment market during the forecast period owing to more intensive treatments such as chemotherapy, surgery, radiation, stem cell transplant, immunotherapy etc. needed in high risk group in order to have best chance of being cured.
Pediatric Neuroblastoma Treatment Market by End User
Based on end user, the market can be segmented into hospitals, cancer specialty centers and others. The hospitals segment is expected to dominate the pediatric neuroblastoma treatment market followed by cancer specialty centers during the forecast period. Frequent visits of patients to hospitals for diagnosis and treatment of cancer can be considered as one of the major factor responsible for the growth of the segment.
Pediatric Neuroblastoma Treatment Market by Region
Based on region, the global pediatric neuroblastoma treatment market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the pediatric neuroblastoma treatment market, followed by Asia Pacific. The growth in North America can be attributed to the high number of ongoing R&D activities, advanced health care infrastructure and better reimbursement plans.
Pediatric Neuroblastoma Treatment Market Prominent Players
Some of the prominent players in the pediatric neuroblastoma treatment market include United Therapeutics Corporation, APEIRON Biologics AG., EUSA Pharma, CELLECTAR BIOSCIENCES, INC., Y-mAbs Therapeutics, Inc., Pfizer Inc., MacroGenics, Inc., Baxter, Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Ltd. among others.